Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Squamous Cell Carcinoma of the Thoracic Esophagus
Alberto Ruol(University of Padua), Ermanno Ancona(University of Padua), Gianfranco Da Dalt(University of Padua), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Matteo Cagol(Istituto Oncologico Veneto), Silvia Michieletto(Istituto Oncologico Veneto), Silvia Mantoan(University of Padua), Francesco Cavallin, Gianpietro Zanchettin(University of Padua), Rita Alfieri(Istituto Oncologico Veneto), Giovanni Zaninotto(Imperial College London), Carlo Castoro(Humanitas University), L. Corti(Istituto Oncologico Veneto), Christian Rizzetto(University of Southern California)
Cited by 74
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k